These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18593683)

  • 21. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating a restrictive formulary system by assessing nonformulary-drug requests.
    Green JA; Chawla AK; Fong PA
    Am J Hosp Pharm; 1985 Jul; 42(7):1537-41. PubMed ID: 4025350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees. An Australian perspective.
    Weekes LM; Day RO
    Drug Saf; 1998 Mar; 18(3):153-9. PubMed ID: 9530535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formulary decisions: then and now.
    Boucher BA
    Pharmacotherapy; 2010 Jun; 30(6 Pt 2):35S-41S. PubMed ID: 20500042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration.
    Ezeife DA; Truong TH; Heng DY; Bourque S; Welch SA; Tang PA
    Cancer; 2015 May; 121(10):1688-93. PubMed ID: 25604014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A national survey on hospital formulary management processes.
    Anagnostis E; Wordell C; Guharoy R; Beckett R; Price V
    J Pharm Pract; 2011 Aug; 24(4):409-16. PubMed ID: 21768310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
    Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
    Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
    Pinkerton JV; Pickar JH
    Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RU-486: legal and policy issues confronting the Food and Drug Administration.
    Muhl C
    J Leg Med; 1993 Jun; 14(2):319-47. PubMed ID: 8340714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementation of a new dantrolene formulation across a multifacility health system.
    Zavilla CM; Skledar S; Lang MB; Gross C
    Am J Health Syst Pharm; 2016 Apr; 73(7):463-7. PubMed ID: 27001988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Availability of comparative efficacy data at the time of drug approval in the United States.
    Goldberg NH; Schneeweiss S; Kowal MK; Gagne JJ
    JAMA; 2011 May; 305(17):1786-9. PubMed ID: 21540422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug formulary decision-making in two regional health authorities in British Columbia, Canada.
    Armstrong K; Mitton C; Carleton B; Shoveller J
    Health Policy; 2008 Dec; 88(2-3):308-16. PubMed ID: 18508151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formulary compliance and pharmacy labor costs associated with systematic formulary management strategy.
    Helmons PJ; Kosterink JG; Daniels CE
    Am J Health Syst Pharm; 2014 Mar; 71(5):407-15. PubMed ID: 24534596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.